ISG Technologies changes name to CedaraPACS and image-guided surgery firm ISG Technologies has changed its name. Now called Cedara Software, the Mississauga, ON-based firm has embarked on a worldwide corporate branding campaign intended to
PACS and image-guided surgery firm ISG Technologies has changed its name. Now called Cedara Software, the Mississauga, ON-based firm has embarked on a worldwide corporate branding campaign intended to highlight the companys healthcare software products and services. The name change and the companys new stock trading symbols are contingent on shareholder approval. Until they receive approval, the firm will continue to trade under ISO (Toronto Stock Exchange) and ISGTF (Nasdaq).
Cedara will be divided into three core businesses: software and service, image management, and image-guided therapy. Two of the three businesses have gained new executive leadership in the past year. The company named Arun Menawat to the post of general manager/president of the software and service division, which develops the companys Image Application Platform software, designed for 3-D post-processing, CT, digital x-ray, MRI, mammography, nuclear medicine, and ultrasound equipment. Cedara has also appointed Alyn Ford to the position of general manager/vice president of its image management business, which develops software products that display, analyze, and store medical images (PNN 6/99).
Can Generative AI Facilitate Simulated Contrast Enhancement for Prostate MRI?
January 14th 2025Deep learning synthesis of contrast-enhanced MRI from non-contrast prostate MRI sequences provided an average multiscale structural similarity index of 70 percent with actual contrast-enhanced prostate MRI in external validation testing from newly published research.
Can MRI Have an Impact with Fertility-Sparing Treatments for Endometrial and Cervical Cancers?
January 9th 2025In a literature review that includes insights from recently issued guidelines from multiple European medical societies, researchers discuss the role of magnetic resonance imaging (MRI) in facilitating appropriate patient selection for fertility-sparing treatments to address early-stage endometrial and cervical cancer.